Iovance Total Operating Expenses from 2010 to 2024

IOVA Stock  USD 12.36  0.14  1.12%   
Iovance Biotherapeutics' Total Operating Expenses is increasing over the years with slightly volatile fluctuation. Overall, Total Operating Expenses is expected to go to about 450.1 M this year. Total Operating Expenses is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. View All Fundamentals
 
Total Operating Expenses  
First Reported
2008-03-31
Previous Quarter
114.5 M
Current Value
107.7 M
Quarterly Volatility
38 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Iovance Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iovance main balance sheet or income statement drivers, such as Depreciation And Amortization of 34.8 M, Interest Expense of 3.6 M or Selling General Administrative of 30.7 M, as well as many exotic indicators such as Price To Sales Ratio of 1.3 K, Dividend Yield of 0.1 or PTB Ratio of 3.11. Iovance financial statements analysis is a perfect complement when working with Iovance Biotherapeutics Valuation or Volatility modules.
  
This module can also supplement Iovance Biotherapeutics' financial leverage analysis and stock options assessment as well as various Iovance Biotherapeutics Technical models . Check out the analysis of Iovance Biotherapeutics Correlation against competitors.
For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.

Latest Iovance Biotherapeutics' Total Operating Expenses Growth Pattern

Below is the plot of the Total Operating Expenses of Iovance Biotherapeutics over the last few years. It is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. Iovance Biotherapeutics' Total Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iovance Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Operating Expenses10 Years Trend
Slightly volatile
   Total Operating Expenses   
       Timeline  

Iovance Total Operating Expenses Regression Statistics

Arithmetic Mean162,741,196
Geometric Mean49,256,122
Coefficient Of Variation104.69
Mean Deviation148,348,784
Median92,877,000
Standard Deviation170,377,450
Sample Variance29028.5T
Range450M
R-Value0.94
Mean Square Error3404.7T
R-Squared0.89
Slope35,963,152
Total Sum of Squares406398.7T

Iovance Total Operating Expenses History

2024450.1 M
2023428.6 M
2022398.9 M
2021342.7 M
2020261.9 M
2019206.9 M
2018128.3 M

About Iovance Biotherapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Iovance Biotherapeutics income statement, its balance sheet, and the statement of cash flows. Iovance Biotherapeutics investors use historical funamental indicators, such as Iovance Biotherapeutics's Total Operating Expenses, to determine how well the company is positioned to perform in the future. Although Iovance Biotherapeutics investors may use each financial statement separately, they are all related. The changes in Iovance Biotherapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Iovance Biotherapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Iovance Biotherapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Iovance Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Operating Expenses428.6 M450.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock:
Check out the analysis of Iovance Biotherapeutics Correlation against competitors.
For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Iovance Stock analysis

When running Iovance Biotherapeutics' price analysis, check to measure Iovance Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iovance Biotherapeutics is operating at the current time. Most of Iovance Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Iovance Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iovance Biotherapeutics' price. Additionally, you may evaluate how the addition of Iovance Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Fundamental Analysis
View fundamental data based on most recent published financial statements
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
CEOs Directory
Screen CEOs from public companies around the world
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Is Iovance Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.89)
Revenue Per Share
0.005
Return On Assets
(0.40)
Return On Equity
(0.82)
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.